Published On: Mon, Jun 19th, 2017

Reviewing Individual Broker Targets Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)


Recently stock market analysts have updated their consensus ratings on shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART).

Most recent broker ratings

06/07/2017 – Integra LifeSciences Holdings Corporation had its “buy” rating reiterated by analysts at UBS. They now have a USD 60 price target on the stock.

05/31/2017 – Integra LifeSciences Holdings Corporation had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 58 price target on the stock.

05/02/2017 – Integra LifeSciences Holdings Corporation had its “sector perform” rating reiterated by analysts at RBC Capital. They now have a USD 48 price target on the stock.

03/22/2017 – Integra LifeSciences Holdings Corporation had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 47 price target on the stock.

01/12/2017 – Integra LifeSciences Holdings Corporation had its “equal-weight” rating reiterated by analysts at Barclays. They now have a USD 42 price target on the stock.

01/06/2017 – Integra LifeSciences Holdings Corporation was upgraded to “market outperform” by analysts at JMP Securities. They now have a USD 50 price target on the stock.

10/28/2016 – Integra LifeSciences Holdings Corporation was upgraded to “buy” by analysts at Lake Street. They now have a USD 92 price target on the stock.

10/04/2016 – Integra LifeSciences Holdings Corporation had its “outperform” rating reiterated by analysts at Oppenheimer. They now have a USD 93 price target on the stock.

09/23/2016 – Integra LifeSciences Holdings Corporation had its “buy” rating reiterated by analysts at Argus. They now have a USD 105 price target on the stock.

07/13/2016 – Integra LifeSciences Holdings Corporation had its “overweight” rating reiterated by analysts at JP Morgan.

11/12/2015 – Citigroup began new coverage on Integra LifeSciences Holdings Corporation giving the company a “buy” rating. They now have a USD 75 price target on the stock.

09/21/2015 – Integra LifeSciences Holdings Corporation was upgraded to “buy” by analysts at Bank of America Merrill Lynch. They now have a USD 79 price target on the stock.

07/29/2015 – Integra LifeSciences Holdings Corporation was upgraded to “outperform” by analysts at Raymond James.

05/05/2015 – Integra LifeSciences Holdings Corporation was upgraded to “buy” by analysts at Zacks. They now have a USD 73 price target on the stock.

05/04/2015 – Integra LifeSciences Holdings Corporation was upgraded to “outperform” by analysts at Wells Fargo.

Integra LifeSciences Holdings Corporation has a 50 day moving average of 48.87 and a 200 day moving average of 51.04. The stock’s market capitalization is 3.99B, it has a 52-week low of 40.51 and a 52-week high of 88.86.

The share price of the company (NASDAQ:IART) was up +0.13% during the last trading session, with a high of 53.07 and the volume of Integra LifeSciences Holdings Corporation shares traded was 924301.

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions. It sells products and solutions for dural repair, precision tools and instruments, tissue ablation and neuro critical care. It also sells regenerative technology products for treating acute wounds, such as burns, and chronic wounds, including diabetic foot ulcers and surgical tissue repair. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery.